About Evotec and Novo Nordisk
Evotec is a drug discovery alliance and development partnership company. The Company operates worldwide and provides the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. Evotec has assembled top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in a broad range of therapeutic areas. Evotec builds partnerships that translate exciting, early-stage academic science into pipeline programs for pharma and biotech. As part of this initiative, Evotec has created an integrated accelerator-by-award framework called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency). For additional information, please visit www.evotec.com and follow us on Twitter and LinkedIn.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. To learn more visit www.novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
An exciting opportunity to develop scientific breakthroughs into life changing medicines is to partner with innovators and entrepreneurs in biotech and academia. LAB eN² is driven from Novo Nordisk’s Bio Innovation Hub, a cross-disciplinary R&D unit based in Boston with the mission to drive an externally anchored portfolio of co-created therapeutic concepts, as well as technology and delivery projects. To learn more visit Bio Innovation Hub (novonordisk.com).